MedTrace Logo

Smoking Relapse Prevention in Schizophrenia

NCT00320697 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-09-27

No results posted yet for this study

Summary

This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.

Conditions

Interventions

DRUG

bupropion + nicotine patch + nicotine gum or lozenges

Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.

DRUG

Placebo pill + placebo patch

Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.

Sponsors & Collaborators

  • North Suffolk Mental Health Association

    lead OTHER

Principal Investigators

  • A Eden Evins, MD, MPH · North Suffolk Mental Health Association

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-10-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320697 on ClinicalTrials.gov